SCHEMBL22036036

SCHEMBL22036036

COc1nc(N(C)CCCO)ncc1-c1ccc(Oc2cncc(-c3cn[nH]c3)c2)c(C)n1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 5/20 0.37
▸ FGFR2 P21802 5/20 0.37
▸ FGFR4 P22455 5/20 0.37
▸ FGFR3 P22607 5/20 0.37
▸ KDR P35968 5/20 0.37
▸ FLT3 P36888 3/20 0.37
▸ CSF1R P07333 2/20 0.32
▸ PDGFRA P16234 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.31
▸ ROCK2 O75116 2/20 0.31
▸ MDM2 Q00987 2/20 0.30
▸ PLAU P00749 1/20 0.30
▸ CLK2 P49760 1/20 0.30
▸ HIPK1 Q86Z02 1/20 0.30
▸ DYRK2 Q92630 1/20 0.30
▸ HIPK2 Q9H2X6 1/20 0.30
▸ HIPK3 Q9H422 1/20 0.30
▸ CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823995 0.88 CSF1R (0.42) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22036854 0.87 CSF1R (0.42) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22036035 0.86 MDM2 (0.36) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22036509 0.86 CSF1R (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL21824002 0.79 CSF1R (0.36) KDRFLT3CSF1RPDGFRAMDM2
SCHEMBL21980611 0.79 CSF1R (0.39) KDRFLT3CSF1RPDGFRAMDM2
SCHEMBL21980614 0.77 CSF1R (0.39) KDRFLT3CSF1RPDGFRA
SCHEMBL22036855 0.76 CSF1R (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL21824004 0.76 CSF1R (0.57) KDRFLT3CSF1RPDGFRA
SCHEMBL30673534 0.76 CSF1R (0.57) KDRFLT3CSF1RPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-09-28 — — US disclosed
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY FAR1, CSF1R, CSF3R FGFR1 1240/4885FGFR2 1829/4885FGFR4 1220/4885
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy FAR1, CSF1R, CSF3R FGFR1 1240/4885FGFR2 1829/4885FGFR4 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback